Ftse Mib
34.744,21
0,73%
DAX
18.635,54
0,82%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
69.076,64
1,96%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Compugen Ltd (CGEN) Compugen Ltd (CGEN) Notizie

Compugen Ltd

CGEN
2,19
0,02 (0,92%)
Pre Mercato
Ultimo aggiornamento: 11:22:17
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/5/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/5/202413:00PRNUSCompugen to Receive Milestone Payment Triggered by Dosing of..
20/5/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/5/202413:00PRNUSCompugen Reports First Quarter 2024 Results
20/5/202412:59IHMARKETNEWSU.S. Index Futures Edge Slightly Higher in Pre-Market..
16/5/202413:00PRNUSCompugen Publishes Paper in Cancer Immunology Research on..
15/5/202413:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/5/202413:00PRNUSCompugen Appoints David Silberman as Chief Financial Officer
06/5/202413:00PRNUSCompugen to Release First Quarter 2024 Results on Monday,..
25/4/202413:00PRNUSCompugen to Present New Clinical Data Showing COM701 Triple..
10/4/202413:00PRNUSCompugen Publishes Paper in Cancer Immunology Research..
03/4/202413:00PRNUSCompugen to Participate in Two Upcoming Investor Conferences
11/3/202412:00PRNUSCompugen Selected for two Oral Presentations at the Keystone..
06/3/202413:00PRNUSCompugen to Present Data Reflecting its Diversified..
05/3/202422:06EDGAR2Form 20-F - Annual and transition report of foreign private..
05/3/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202413:00PRNUSCompugen Reports Fourth Quarter and Full Year 2023 Results
05/3/202412:05IHMARKETNEWSU.S. Futures Dip, Crude Oil Fluctuates
26/2/202413:00PRNUSCompugen to Present at the Leerink Partners Global Biopharma..
20/2/202413:00PRNUSCompugen to Release Fourth Quarter and Full Year 2023..
15/2/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/2/202413:00PRNUSCompugen Announces Appointment of Michelle Mahler M.D. as..
08/1/202413:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202413:05PRNUSCompugen to Receive $10 Million Milestone Payment Following..
08/1/202413:00PRNUSCompugen Regains Compliance with Nasdaq Minimum Bid Price..
19/12/202315:30APSStrong Open For Biotech Following Exclusive Agreement..
19/12/202313:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202313:10PRNUSCompugen will be Eligible to Receive $10 Million Milestone..
19/12/202313:05PRNUSCompugen to Host Conference Call to Discuss Exclusive..
19/12/202313:00BWGilead and Compugen Announce Exclusive License Agreement for..
07/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202313:00PRNUSCompugen Reports Third Quarter 2023 Results
06/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202313:00PRNUSCompugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity..
03/11/202321:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/11/202321:35PRNUSCompugen Announces Receipt of Nasdaq Minimum Bid Price..
31/10/202314:00PRNUSCompugen to Present New Data at SITC 2023 Suggesting Leading..
24/10/202313:00PRNUSCompugen to Release Third Quarter 2023 Results on Tuesday,..
03/10/202313:00PRNUSCompugen to Present at Single Cell Genomics 2023 Meeting
02/10/202313:00PRNUSCompugen Expands Intellectual Property with New Japanese..
27/9/202315:00PRNUSCompugen to Present New Clinical and Pre-Clinical Data in..
21/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/8/202313:00PRNUSCompugen to Present at the H.C. Wainwright 25th Annual..
23/8/202314:00EDGAR2Form 20-F/A - Annual and transition report of foreign..
07/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202313:00PRNUSCompugen Reports Second Quarter 2023 Results
24/7/202313:00PRNUSCompugen to Release Second Quarter 2023 Results on Monday,..
17/7/202313:00PRNUSCompugen Wins on PVRIG European Patent Opposition Pursued by..
22/6/202313:00PRNUSCompugen Doses First Patient in Triple Immunotherapy..
Apertura: Min: Max:
Chiusura: 2,17

La tua Cronologia

NASDAQ
CGEN
Compugen
COIN
FOTABTC
Fortuna
BTRX
FNSABTC
Finschia
CRTO
OSMOUSD
Osmosis
BINA
RSRBTC
KRKN
IDEXUSD
IDEX Token
LSE
EBOX
Tritax Eurobox
NASDAQ
CTHR
Charles and Colvard
NASDAQ
EVMXX
Eaton Vance Money Market Fund
LSE
RENX
Renalytix
LSE
68ZE
Investec Bnk 25
USOTC
MDDCF
Media Do (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network